[{"data":1,"prerenderedAt":154},["ShallowReactive",2],{"drug-pimecrolimus":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":34,"contraindications":56,"warnings":66,"renal":74,"monitoring":75,"interactions":76,"review":77,"examples":80,"atc":81,"iran":83,"links":99,"populations":114,"usApproval":149},"pimecrolimus",1,{"fa":7,"en":8},"پیمکرولیموس کرم ۱٪","Pimecrolimus cream 1%","dermatology",{"fa":11,"en":12},"مهارکننده کلسینورین موضعی","Topical calcineurin inhibitor",[14],{"name":15,"market":16},"Elidel","US",[18,19,20],"elidel","الیدل","پیمکرولیموس",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":29,"refs":30},"cream-1","cream","topical","Pimecrolimus 1% cream",{"amount":5,"unit":28,"perUnit":28},"application",[16],[31],{"source":32,"section":33},"fda-pimecrolimus","3",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":46,"dose":47,"refs":51},"ad","atopic-dermatitis",{"fa":39,"en":40},"درماتیت آتوپیک خفیف تا متوسط (خط دوم، ۲ سال به بالا) — دو بار در روز","Mild–moderate atopic dermatitis (second line, ≥2 y) — twice daily",{"minAge":42},{"value":43,"unit":44},2,"year","notCalculated","mg",{"reason":48},{"fa":49,"en":50},"لایه نازک دو بار در روز تا رفع علائم؛ اگر بیش از ۶ هفته ادامه یافت، بیمار دوباره معاینه شود. مصرف طولانی و مداوم نه؛ فقط روی نواحی درگیر.","Thin layer twice daily until signs resolve; re-examine if symptoms persist beyond 6 weeks. Avoid continuous long-term use; affected areas only.",[52,54],{"source":32,"section":53},"2",{"source":32,"section":55},"1",[57],{"id":58,"severity":59,"text":60,"refs":63},"hyper","block",{"fa":61,"en":62},"حساسیت به پیمکرولیموس.","Hypersensitivity to pimecrolimus.",[64],{"source":32,"section":65},"4",[67],{"text":68,"refs":71},{"fa":69,"en":70},"هشدار جعبه‌ای: ایمنی طولانی‌مدت ثابت نشده؛ موارد نادر بدخیمی (پوست، لنفوم). در نقص ایمنی و زیر ۲ سال مصرف نشود.","Boxed warning: long-term safety not established; rare malignancy (skin, lymphoma). Not for immunocompromised patients or under 2 years.",[72],{"source":32,"section":73},"Boxed Warning",[],[],[],{"status":78,"reviewer":79,"date":79},"unverified",null,[],[82],"D11AH02",{"status":84,"forms":85,"refs":94},"registered",[86,90],{"code":87,"en":88,"fa":89},"07760","PIMECROLIMUS 1% 15G CREAM","کرم پیمکرولیموس ۱ درصد ۱۵ گرم",{"code":91,"en":92,"fa":93},"05421","PIMECROLIMUS 1% 30G CREAM","کرم پیمکرولیموس ۱ درصد ۳۰ گرم",[95],{"source":96,"section":97,"url":98},"darooyab-generic","G-2308\u002FPimecrolimus","https:\u002F\u002Fwww.darooyab.ir\u002FG-2308\u002FPimecrolimus",[100,104,108,111],{"kind":101,"url":102,"label":103},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021302","NDA021302",{"kind":105,"url":106,"label":107},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=6601e43e-ce7d-446a-8568-8e7b24b86f06","FDA Pimecrolimus",{"kind":109,"url":110,"label":82},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=D11AH02",{"kind":112,"url":98,"label":113},"darooyab","Pimecrolimus",{"pregnancy":115,"lactation":124,"pediatric":133,"geriatric":141},{"level":116,"text":117,"quote":120,"refs":121},"caution",{"fa":118,"en":119},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Pregnancy Category C There are no adequate and well-controlled studies with Pimecrolimus Cream, 1% in pregnant women.",[122],{"source":32,"section":123},"8.1",{"level":125,"text":126,"quote":129,"refs":130},"avoid",{"fa":127,"en":128},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in nursing infants from pimecrolimus, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.",[131],{"source":32,"section":132},"8.3",{"level":116,"text":134,"quote":137,"refs":138},{"fa":135,"en":136},"برچسب: فقط ۲ سال به بالا و خط دوم؛ زیر ۲ سال اندیکاسیون ندارد.","Label: only ≥2 years and second line; not indicated under 2 years.","Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age",[139],{"source":32,"section":140},"8.4",{"level":116,"text":142,"quote":145,"refs":146},{"fa":143,"en":144},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Nine (9) subjects ≥65 years old received Pimecrolimus Cream, 1% in Phase 3 trials.",[147],{"source":32,"section":148},"8.5",{"kind":150,"refs":151,"id":103},"NDA authorized generic",[152],{"source":32,"section":153},"SPL approval \u002F marketing category",1792111464456]